Kornimate/medical-research-clean huggingface dataset:
recovery after intensive care study

Conditions: Follow up; Outcome; Intensive Care Unit Syndrome

Summary: post-icu long term sequelae- defined as "post intensive care syndrome" (pics) manifest with a wide spectrum of psychological and cognitive impairments, affecting over two-thirds of icu survivors and leading to increased rehospitalization, health care costs, impaired quality of life (qol), inability to return to work and burden for families. the prevalence of post-traumatic stress symptoms (ptsd), anxiety symptoms, and depression after icu stay is high and has been demonstrated in up to 50% of post-icu population. therefore, over the last years, an important effort has been made for the development of icu aftercare and follow-up clinics with the aim to detect and to minimize post-icu sequelae and improve outcomes. however, the utility of these follow-up programs and their effect on outcome has not been completely demonstrated.

this is a single center, prospective observational study, which will be conducted at policlinico san martino hospital, genova, italy. patients admitted to the icu from more than 72 hours will be consecutively included during a 2 years period. the primary objective is to assess the incidence of post-discharge mortality in patients admitted in icu at 12 months. secondary objectives include the evaluation at 3, 6 and 12 months of outcome of patients admitted in icu assessing qol, anxiety, depression, ptsd, physical ability, cognitive function, sleep disorder and return to previous life; self- and observer reported cognitive disability at 6 and 12 months after icu discharge; prognostic factors for poor outcome, and emotional and burden of care impact on the patient's caregivers.

Eligibility criteria:
inclusion criteria: * age ≥ 18 years; * all patients acutely admitted in the icu from \>72 hours, for both medical and surgical pathologies. exclusion criteria: * pregnancy; * refuse of consent to enrolment of patient or of the doctor required to give his approval.

Keywords: intensive care unit cognitive dysfunction delirium
low dose bupivacaine spinal for trans uretral prostatectomy.

Conditions: Benign Prostate Hyperplasia

Summary: spinal anesthesia, is used during the transuretheral resection of the prostate.low dose hyperbaric local anesthetics have been used to enhance the resolution of the spinal block. we compared the efficacy and duration of the spinal block with two different bupivacaine baricities. * group i: low dose isobaric group * groupii: low dose hyperbaric group

patients undergoing turp were randomly allocated into two groups. * group i: received fentanyl 20 µgr (0.4ml),heavy bupivacaine 0.5% (1.5 ml)and normal saline % 0.9 nacl ( 1.1ml) * group ii: received fentanyl 20 µgr (0.4 ml), plain bupivacaine 0.5%(1.5 ml) normal saline 0.9% nacl (1.1 ml) in total bupivacaine 0.25% (3ml) intrathecally. onset and duration of the sensory block, the degree of the motor block, side - effects and perioperative analgesic requirement assesed.

Eligibility criteria:
inclusion criteria: * 50-85 years asa 1-4 beni̇gn prostat hyperplasi̇ exclusion criteria: * allergy of study drugs * morbid obesity * spinal anesthesia contrindications * bleeding dyscrasias

Keywords: low dose different baricity spinal anesthesia
daily variability of platelet aggregation in patients with myocardial infarction treated with prasugrel and ticagrelor

Conditions: Acute Myocardial Infarction

Summary: the aim of this study is to compare circadian variability of antiplatelet effect of prasugrel and ticagrelor maintenance doses during the initial days after acute myocardial infarction.

prasugrel and ticagrelor are two oral p2y12 receptor antagonists recommended as a part of dual antiplatelet therapy with aspirin in patients with acute myocardial infarction. both drugs exert comparable antiplatelet effect following a loading dose. however, pharmacodynamic differences exist between these p2y12 receptor inhibitors. prasugrel is a prodrug that requires hepatic activation and permanently binds to platelet p2y12 receptors, whereas ticagrelor is an active drug and blocks p2y12 receptors reversibly. another important difference is that prasugrel maintenance dose is administered once daily, while ticagrelor requires next dosage every 12 hours. these fundamental distinctions may affect the degree of platelet inhibition on maintenance doses during the first days after acute myocardial infarction.

Eligibility criteria:
inclusion criteria: * provision of informed consent prior to any study specific procedures * diagnosis of acute st-segment elevation myocardial infarction or acute non-st-segment elevation myocardial infarction * male or non-pregnant female, aged 18-75 years old * provision of informed consent for angiography and percutaneous coronary intervention exclusion criteria: * treatment with ticlopidine, clopidogrel, prasugrel or ticagrelor within 14 days before the study enrollment * hypersensitivity to ticagrelor or prasugrel * contraindications for ticagrelor or prasugrel * current treatment with oral anticoagulant or chronic therapy with low-molecular-weight heparin * active bleeding * history of ischemic stroke or transient ischemic attack * history of intracranial hemorrhage * recent gastrointestinal bleeding (within 30 days) * history of moderate or severe hepatic impairment * history of major surgery or severe trauma (within 3 months) * patient required dialysis * manifest infection or inflammatory state * concomitant therapy with strong cyp3a inhibitors (ketoconazole, itraconazole, voriconazole, telithromycin, clarithromycin, nefazadone, ritonavir, saquinavir, nelfinavir, indinavir, atazanavir) or strong cyp3a inducers (rifampicin, phenytoin, carbamazepine, dexamethasone, phenobarbital) within 14 days and during study treatment * body weight below 60 kg

Keywords: prasugrel ticagrelor vasp platelet reactivity stemi nstemi
men with fibromyalgia or chronic widespread pain - effect of exercise on symptoms and body functions

Conditions: Fibromyalgia; Pain

Summary: a controlled randomised trial (crt). 60 men who fulfil the acr-criteria for fibromyalgia or chronic widespread pain (wolfe 1990) participate in the study. the main objective of the study is to compare the effect of a graded strength training program and a low intensive pool exercise program.

a controlled randomised trial (crt). 60 men who fulfil the acr-criteria for fibromyalgia or chronic widespread pain (wolfe 1990) participate in the study. 40 patients (in the city uddevalla) are randomised into two groups; low intensive temperate pool exercise program, and graded strength training program. the study period is 12 weeks. 20 patients (in the city alingsås) make a reference group who is asked to continue their normal activities during the study period. primary outcomes are fatigue (using the multidimensional fatigue inventory and vas for global fatigue)and muscle strength (using steve strong, isobex and the grippit). several other self-administered instruments was used.

Eligibility criteria:
inclusion criteria: male patients with fibromyalgia or chronic widespread pain exclusion criteria: other severe physical or psychiatric disorders.

Keywords: fibromyalgia widespread pain fatigue physical exercise
behavioral change following alzheimer's disease (ad) biomarker disclosure

Conditions: Mild Cognitive Impairment; Alzheimer Disease; Amnestic Mild Cognitive Disorder

Summary: the proposed project will assess long-term changes to health/lifestyle, advanced planning, and research engagement that black and white patients with amnestic mild cognitive impairment (amci) make following disclosure of positron emission tomography-based amyloid and tau burden and associated risk of conversion to dementia-alzheimer's type. healthcare access will be explored as potential barrier to or facilitator of behavior change.


Eligibility criteria:
inclusion criteria: * diagnosed with amnestic mild cognitive impairment within the past 12 months, * available pet aβ and tau imaging exclusion criteria: * significant neurologic diagnosis (e.g., alzheimer's dementia or other neurodegenerative dementia, parkinson's disease, seizure disorder, tumor, multiple sclerosis) * neurologic injury (e.g., significant stroke or moderate-severe head injury, defined by loss of consciousness \> 5 minutes, presence of significant post-traumatic amnesia, or the need for extended hospitalization or intervention) * motor abnormalities indicative of a non-ad etiology * severe mental illness (e.g., bipolar disorder, psychosis), moderate-severe mood or anxiety disorder, active substance use disorder (o reduce the likelihood of severe psychological distress, participants must screen negative for moderate-severe depressive or anxiety symptoms at study enrollment.) * inability to provide independent informed consent.

Keywords: ad biomarkers alzheimer's disease mild cognitive impairment amnestic mild cognitive disorder
single versus combined antibiotic therapy for bacterial peritonitis in capd patients

Conditions: Peritonitis

Summary: to compare the efficacy of single versus combined antibiotic therapy for bacterial peritonitis in capd patients.

to compare relapse and recurrent rate of peritonitis between single and combined antibiotic regimens for bacterial peritonitis in capd patients.

Eligibility criteria:
inclusion criteria: * age \>/= 18 years old * esrd patients on continuous ambulatory peritoneal dialysis more than 4 weeks * presence of symptom or sign of peritonitis * presence of wbc \>100cell/mm3 with pmn \>50% in peritoneal dialysate or gram stain positive for gram positive or gram negative bacteria exclusion criteria: * presence of polymicrobial organism, non-fermentative gram negative organism, fungus, mycobacteria in peritoneal fluid or culture-negative * peritonitis from the organisms that required combined antibiotic therapy according to ispd guideline 2010 * hospital-acquired peritonitis * presence of catheter-related infection * history of peritonitis within 4 weeks * currently taking antibiotic * allergic to the antibiotic that used in the study(penicillin or cephalosporin or quinolone or aminoglycoside)

Keywords: peritoneal dialysis peritonitis
ensartinib in non-small cell lung cancer patients with positive alk

Conditions: Solid Tumor; Non-Small Cell Lung Cancer Metastatic

Summary: this study is aimed to determine the maximum tolerated dose of ensartinib, an oral alk inhibitor in chinese patients with alk-positive non-small cell lung cancer

the initial purpose of the study is to determine the largest amount of ensartinib that can be safely given to humans. an expansion phase will be conducted to assess the preliminary anti-tumor activity in alk-positive non-small cell lung cancer once the recommended phase 2 dose has been established.

Eligibility criteria:
inclusion criteria: * histologically or cytologically confirmed diagnosis of advanced solid tumor malignancy * for the expanded cohort portion of the study, patients must have nsclc with alk genomic alterations positive by fish or ihc * eastern cooperative group ecog) performance status score of 0 or 1 * adequate organ system function * male patients willing to use adequate contraceptive measures; female patients who are not of child-bearing potential, and female patients of child-bearing potential who agree to use adequate contraceptive measures * measurable disease per recist * willingness and ability to comply with the trial and follow-up procedures * written informed consents are required to indicate that the patients are aware of the investigational nature of the study exclusion criteria: * current use of anticancer therapy. * use of an investigational drug within 14 days or 5 half-lives (whichever is shorter) prior to the first dose of ensartinib * any major surgery, radiotherapy, or immunotherapy within the last 21 days. * chemotherapy regimens with delayed toxicity within the last 4 weeks. * chemotherapy regimens given continuously or on a weekly basis with limited potential for delayed toxicity within the last 2 weeks. * prior stem cell transplant * patients with a known allergy or delayed hypersensitivity reaction to drugs chemically related to ensartinib or to the active ingredient of ensartinib * prior use of alk tkis with the exception of crizotinib * primary cns tumors or meningeal metastasis * pregnant or breastfeeding female * presence of active gastrointestinal (gi) disease or other condition that will interfere significantly with the absorption, distribution, metabolism, or excretion of ensartinib * clinically significant cardiovascular disease. * psychological, familial, sociological, or geographical conditions that do not permit compliance with the protocol * concurrent condition evaluated by investigator would jeopardize compliance with the protocol or would impart excessive risk associated with study participation that would make it inappropriate for the patient to be enrolled * inability or unwillingness to comply with study and/or follow-up procedures outlined in the protocol
effectiveness and safety of atypical antipsychotic agents in augmenting ssri-refractory obsessive-compulsive disorder

Conditions: SSRI-Refractory Obsessive-Compulsive Disorder

Summary: objective: although atypical antipsychotic drugs (aapds) have been found effective in the augmentation of serotonin reuptake inhibitors (sris) for treatment-resistant obsessive-compulsive disorder (ocd) in short terms trials, there are few data on the effectiveness and safety of these agents in clinical settings over the long term. method: subjects (n=46) who responded to selective sris (ssris) in an initial 12-week trial were continued on sri-monotherapy plus cognitive-behavioral therapy (cbt) for one year. subjects (n=44) who failed to respond to ssris were randomly assigned to one of 3 aapds such as risperidone and were consecutively treated using ssri+aapd combined with cbt for a year.

more recently, second-generation atypical antipsychotic drugs (aapd) that modulate both 5-ht and da function, such as risperidone (ris), olanzapine (olz) and quetiapine (qet), have been found effective in the augmentation of ssris for treatment-resistant ocd. nevertheless, the aapds have been associated with common and serious adverse effects, such as body weight (bw) gain and metabolic dysregulation. metabolic dysregulation includes glucoregulatory dysfunction and dyslipidemia. indeed, studies of some aapd in ssri-refractory ocd patients have similarly reported significant bw gain. aapd-induced bw gain may influence patients' adherence to medication and places them at risk for a broad range of medical problems. most work on aapds in treatment-refractory ocd has been conducted in the form of short-term efficacy studies. there have been fewer studies of the effectiveness, safety, and tolerability of these agents in the context of a clinic where cbt is also provided, and where treatment is continued for a significant period of time. in the current effectiveness study, we sought to examine the response of ssri-refractory patients to augmentation with aapds, comparing adverse events in such compared to a control group of ssri responders.

Eligibility criteria:
inclusion criteria: * male or female, 18 years of age or over * patients were diagnosed as having obsessive-compulsive disorder by the structured clinical interview for dsm-iv patient version (scid-p) * they received standardized treatment for at least 1 year at the ocd clinic in our university hospital. * each subject gave written informed consent to take part after receiving a complete description of this study. * all subjects were free of medical illness based on results of physical examination and screening tests of blood and urine, and no subjects received any lipid lowering or hypoglycemic agent during the 1-year study period. exclusion criteria: * current clinically significant medical conditions such as diabetes

Keywords: obsessive-compulsive disorder augmentation treatment ssri-refractory
vinblastine and methotrexate in treating children with desmoid tumors

Conditions: Desmoid Tumor

Summary: rationale: drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. combining more than one drug may kill more tumor cells. purpose: phase ii trial to study the effectiveness of chemotherapy with vinblastine and methotrexate in treating children who have desmoid tumors that are recurrent or untreatable with surgery or radiation therapy.

objectives: i. estimate the efficacy and toxicity of vinblastine and methotrexate for newly diagnosed or recurrent desmoid tumors in children who are not good candidates for treatment with surgery or radiation therapy. outline: patients receive vinblastine and methotrexate iv weekly for 26 weeks, then every 2 weeks for an additional 26 weeks. treatment continues for a maximum of 1 year in the absence of unacceptable toxicity or disease progression. patients with a complete response receive an additional 8 doses of chemotherapy. patients are followed every 6 months for 4 years and then annually thereafter. projected accrual: a total of 13-25 patients will be accrued for this study.

Eligibility criteria:
disease characteristics: histologically proven, untreated, primary desmoid tumor (aggressive fibromatosis) for which surgery and/or radiation therapy is not thought to be feasible (prior attempted surgical resection allowed if gross residual disease remains) no other fibroblastic lesions or other fibromatoses allowed recurrent desmoid tumor not previously treated with vinca alkaloids or methotrexate and no chemotherapy since recurrence measurable disease by mri patient characteristics: age: under 19 at time of diagnosis performance status: not specified life expectancy: not specified hematopoietic: hemoglobin normal for age wbc normal for age platelet count normal for age hepatic: bilirubin less than 1.5 times upper limit of normal (uln) for age sgot less than 1.5 times uln for age renal: creatinine less than 1.5 times uln for age prior concurrent therapy: see disease characteristics

Keywords: desmoid tumor
additional effects of joint mobilization in addition to rocabado exercises on alleviating trismus following third molar extraction

Conditions: Trismus

Summary: without appropriate early intervention, prolonged trismus can lead to lasting complications like reduced jaw mobility or temporomandibular joint disorders.therefore joint mobilization will impact on trismus, that will offer valuable insights into how these interventions will affect inflammation, muscle function and overall healing process within tmj besides rocabado exercises that involves a series of movements and stretches targeting the muscles and joints involved in chewing,swallowing and speaking and minimizing muscle tension and opening the mouth, preventing further deterioration of jaw function and improving overall quality of life of individuals. if found effective, this will be added to the literature for the treatment of trismus after third molar extraction.


Eligibility criteria:
inclusion criteria: * referral or consultation from a dentist to confirm the diagnosis of trismus. * age 18-45 years * both genders (male and female) * maximal interincisal opening ≤ 35mm (restricted jaw motion). * unilateral/bilateral impacted lower third molars. * 3 days post mandibular third molar extraction exclusion criteria: * local infection or bleeding post third molar extraction. * patients with acute pericoronitis * patient undergoing chemotherapy and radiotherapy. * type i diabetes, renal failure and chronic liver disease were excluded as immunocompromised state. * pregnant or lactating women. * cyst or tumor associated with impacted tooth
prognostic factors of patients with adhf

Conditions: Acute Decompensated Heart Failure

Summary: to explore the prognostic indicators for patients with adhf

according to esc guidelines for the diagnosis of acute heart failure 2008, patients with adhf were diagnosed, and their medical history, laboratory examination and treatment plan were retrospectively analyzed, and the patients were followed up for 1 year. the 1-year outcomes of patients were analyzed to explore the prognostic indicators for patients with adhf

Eligibility criteria:
inclusion criteria: * patients with adhf diagnosed according to esc guidelines for the diagnosis of acute heart failure 2008 exclusion criteria: * disorders of the hematopoietic system, history of cancer and/or previous treatment with chemotherapy, the infection caused by various pathogens, chronic inflammatory conditions, glucocorticoid therapy and/or histories of glucocorticoid use 3 months before the admission and acute myocardial infarction or coronary revascularization within the past 6 months. also, patients who did not have a differential wbc count or who were lost to follow-up were excluded.

Keywords: monocyte count heart failure acute decompensated heart failure all-cause death
registry to collect health information related to fibrolamellar cancer

Conditions: Fibrolamellar Cancer; FLC; Liver Cancer

Summary: the purpose of this study is to collect information about people with fibrolamellar cancer (flc). this study is a registry of people with flc around the world. this study will involve collecting information about participants, their medical history and the regular medical care they receive for flc. the study will not provide treatment for your cancer.


Eligibility criteria:
inclusion criteria: * age 13 years or older. * personal history of histologically proven fibrolamellar carcinoma (clinical or radiographical suspicion of flc must be confirmed at msk or an external hospital) * participants must have access to electronic devices that meet the following minimum requirements: * ability to connect to the internet * capability of running modern internet browers (such as google chrome, internet explorer, safari, or mozilla firefox). * participants must have a google account exclusion criteria: * participants residing in the european union (eu).

Keywords: fibrolamellar cancer liver cancer 20-543 memorial sloan kettering cancer
healing process and blood sugar level following local anesthetic infiltration with and without vasoconstrictor

Conditions: Diabetes; Anesthesia, Local

Summary: evaluating the healing of the extraction socket and the glycemic levels before, and after injection of local anesthesia with and without vasoconstrictor in diabetic patients


Eligibility criteria:
inclusion criteria: * inclusion criteria patients over 20 years and under 60 years of age * dm controlled by medication * requiring a tooth extraction in the maxilla, with an indication of the intra-alveolar technique for periodontal reasons. * only participants that are willing to control and record blood glucose level throughout the study period. exclusion criteria: * patients with any significant medical condition (besides dm) * alcoholic individuals * patients on drugs that affect the central nervous systems * patients who reported the use of drugs that might interfere with pain sensitivity * pregnant and lactating women * patients with hypersensitivity to local anesthetics or non-steroidal anti-inflammatory drugs (nsaids).